Lorecivivint (inferred)
Knee Osteoarthritis
Phase 3Active
Key Facts
About Biosplice Therapeutics
Biosplice Therapeutics is a private, clinical-stage biotech based in San Diego, founded in 2012, with a novel platform targeting alternative splicing via CLK/DYRK kinases. The company is advancing a pipeline led by lorecivivint for osteoarthritis, which has progressed to Phase 3 trials, representing a potential disease-modifying therapy in a large, underserved market. Its platform also holds promise in oncology and other degenerative diseases, though it faces significant scientific, clinical, and competitive risks inherent in pioneering a new drug class.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Progenza | Cambium Bio | Phase 1/2a |
| MAG200 | Magellan | Phase 3 |
| MUTI™ Knee Replacement | Meril | Commercial |
| DUROLANE | Bioventus | Commercial |
| XSTEM | Xintela | Phase I/IIa |
| Stempeucel® | Stempeutics Research | Commercial |
| Lipogems System for Knee Osteoarthritis | Lipogems International | Phase 3 |
| Signature Cord Prime™ | Arugula Sciences | Phase 1 |
| Knee Osteoarthritis Study | Arizona Research Center | Not Specified |
| 4P004 | 4Moving Biotech | Phase 2a |
| Regenerative Cell Therapy for Osteoarthritis | InGeneron | Phase 3 |
| ArthroCart | Arthro Biotech | Preclinical |